14 
Containing Recombinant D1& Molecules will be evaluated by the Large-Scale 
Review \ forking Group. The working group recommendation concerning the proposal , 
as well as the proposal, would then be transmitted to the RAC. 
Dr. McKinney said the concept of appointing an industrial advisory group or an 
industrial liaison representative to the RAC and/or the Large-Scale Review 
Working Group has been offered at previous meetings. Dr. Be ms said the current 
arrangement permits any individual or group to present their concerns to the 
working group or to RAC. Cue problem with the concept of an industrial liaison 
representative or advisory group is the question of who will fill this role. 
Interests in industry are frequently parochial, and no advisory body may be 
broad enough to cover all interests. Er. Waitz said industry's primary concern 
is to have representation of a broad industrial view point. Er. Ross of 
Genentech, Inc., supported the concept of appointing a nonvoting liaison 
representative/group to the Large-Scale Review Working Group for the purpose 
of providing industrial technical information. 
Dr. McKinney then questioned the proposal to include toie Large-Scale Recommenda- 
tions in the Guidelines. He said industry interaction with the NIH in the area 
of recombinant ENA activities occurs under the voluntary compliance program 
(Part VI) of the Guidelines. He pointed out that RAC has recently limited its 
evaluation of industry proposals to considering only the biology. Er. Waitz 
said incorporating the Large-Scale Recommendations into the Guidelines would 
facilitate voluntary compliance. By formalizing the Large-Scale Recommend at ions, 
the NIH would provide an accepted standard of authority. Er. Ross supported 
the concept of incorporating the Large-Scale Recommendations into the Guidelines. 
[511 
